ABBV Jun 2024 230.000 call
| Previous close | 2.8800 |
| Open | 0.5700 |
| Bid | 0.3500 |
| Ask | 0.7900 |
| Strike | 230.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.5700 - 0.7300 |
| Contract range | N/A |
| Volume | |
| Open interest | 14 |
- Motley Fool
2 of the Best Dividend Stocks to Own in 2023
In either case, it's a good idea to add some dividend stocks to your portfolio. If you want to benefit from passive income and potential growth, I've got two stocks in mind. The stocks I'm talking about also have reached a turning point that could lead to earnings growth down the road.
- PR Newswire
Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'. This is a customer centric approach, which supports continued innovation and provides cutting-edge products and technologies to help practitioners and patients' aesthetics needs today and for the future.
- Motley Fool
3 Reasons to Buy AbbVie and 2 Reasons Not to Buy
2023 is expected to be an important year for AbbVie (NYSE: ABBV). The pharmaceutical company is facing its first biosimilar competition in the United States. It's big news because it involves AbbVie's monoclonal antibody blockbuster therapy, Humira, which is on track to generate a second consecutive year of $20 billion-plus in revenue in 2022.
